Tanvex BioPharma, Inc. (6541.TW)

TWD 58.5

(-3.62%)

Inventory Summary of Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc.'s latest annual inventory in 2023 was 108.28 Million TWD , down -36.62% from previous year.
Tanvex BioPharma, Inc.'s latest quarterly inventory in 2024 Q2 was 106.67 Million TWD , down -4.06% from previous quarter.
Tanvex BioPharma, Inc. reported annual inventory of 170.84 Million TWD in 2022, up 89.13% from previous year.
Tanvex BioPharma, Inc. reported annual inventory of 90.33 Million TWD in 2021, up 80.37% from previous year.
Tanvex BioPharma, Inc. reported quarterly inventory of 111.18 Million TWD for 2024 Q1, up 2.68% from previous quarter.
Tanvex BioPharma, Inc. reported quarterly inventory of 141.9 Million TWD for 2023 Q2, up 0.51% from previous quarter.

Annual Inventory Chart of Tanvex BioPharma, Inc. (2023 - 2013)

Historical Annual Inventory of Tanvex BioPharma, Inc. (2023 - 2013)

Year	Inventory	Inventory Growth
2023	108.28 Million TWD	-36.62%
2022	170.84 Million TWD	89.13%
2021	90.33 Million TWD	80.37%
2020	50.08 Million TWD	-4.06%
2019	52.2 Million TWD	82.67%
2018	28.57 Million TWD	103.04%
2017	-941.45 Million TWD	40.46%
2016	-1.58 Billion TWD	-346647.15%
2015	-456 Thousand TWD	0.0%
2014	- TWD	0.0%
2013	- TWD	0.0%

Year	Inventory	Inventory Growth
2024 Q2	106.67 Million TWD	-4.06%
2024 Q1	111.18 Million TWD	2.68%
2023 Q2	141.9 Million TWD	0.51%
2023 FY	108.28 Million TWD	-36.62%
2023 Q4	108.28 Million TWD	-18.65%
2023 Q1	141.18 Million TWD	-17.36%
2023 Q3	133.11 Million TWD	-6.2%
2022 Q2	172.11 Million TWD	36.63%
2022 Q4	170.84 Million TWD	-13.93%
2022 Q3	198.5 Million TWD	15.33%
2022 Q1	125.96 Million TWD	39.45%
2022 FY	170.84 Million TWD	89.13%
2021 FY	90.33 Million TWD	80.37%
2021 Q4	90.33 Million TWD	45.36%
2021 Q1	52.09 Million TWD	4.01%
2021 Q2	50.93 Million TWD	-2.22%
2021 Q3	62.14 Million TWD	22.01%
2020 Q4	50.08 Million TWD	0.67%
2020 Q1	57.87 Million TWD	10.87%
2020 Q2	51.73 Million TWD	-10.61%
2020 Q3	49.74 Million TWD	-3.85%
2020 FY	50.08 Million TWD	-4.06%
2019 Q1	44.55 Million TWD	55.89%
2019 Q2	47.5 Million TWD	6.64%
2019 FY	52.2 Million TWD	82.67%
2019 Q4	52.2 Million TWD	-16.43%
2019 Q3	62.46 Million TWD	31.48%
2018 Q4	28.57 Million TWD	65.33%
2018 FY	28.57 Million TWD	103.04%
2018 Q3	17.28 Million TWD	77.88%
2018 Q2	9.71 Million TWD	0.0%
2018 Q1	- TWD	0.0%
2017 Q4	- TWD	0.0%
2017 FY	-941.45 Million TWD	40.46%
2017 Q1	- TWD	0.0%
2017 Q2	- TWD	0.0%
2017 Q3	- TWD	0.0%
2016 Q3	- TWD	0.0%
2016 Q1	- TWD	0.0%
2016 FY	-1.58 Billion TWD	-346647.15%
2016 Q2	- TWD	0.0%
2016 Q4	- TWD	0.0%
2015 Q4	- TWD	0.0%
2015 Q2	- TWD	0.0%
2015 Q1	- TWD	0.0%
2015 FY	-456 Thousand TWD	0.0%
2014 FY	- TWD	0.0%
2014 Q4	- TWD	0.0%
2014 Q3	- TWD	0.0%
2014 Q1	- TWD	0.0%
2013 FY	- TWD	0.0%

Peer Inventory Comparison of Tanvex BioPharma, Inc.

Name	Inventory	Inventory Difference
Apex Biotechnology Corp.	747.71 Million TWD	85.518%
Sinphar Pharmaceutical Co.,Ltd.	839.19 Million TWD	87.097%
Panion & Bf Biotech Inc.	538.09 Million TWD	79.876%
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	1.21 Billion TWD	91.058%
GenMont Biotech Incorporation	88.11 Million TWD	-22.886%
Abnova (Taiwan) Corporation	408.3 Million TWD	73.479%
Adimmune Corporation	526.4 Million TWD	79.429%
Polaris Group	36.35 Million TWD	-197.854%
Energenesis Biomedical CO.,LTD.	733 Thousand TWD	-14672.851%
UnicoCell Biomed Co., Ltd.	5.45 Million TWD	-1886.516%
PELL Bio-Med Technology Co. Ltd.	3.76 Million TWD	-2777.624%